文献速递特殊人群用药

妊娠期齐拉西酮的生理药代动力学模型预测

Physiologically-based pharmacokinetics of ziprasidone in pregnant women.
PubMed 文献 · Br J Clin Pharmacol · 2019-03-11

本研究建立并验证了齐拉西酮的全身生理药代动力学(PBPK)模型,覆盖健康成人、儿童和老年人,并扩展至妊娠状态以评估妊娠期药代动力学变化。模型成功预测了各人群的齐拉西酮处置,模拟显示妊娠妇女暴露与非妊娠妇女无显著差异,提示该特殊人群无需调整剂量。

要点

  • 齐拉西酮PBPK模型在健康成人、儿童和老年人中预测值与观察值差异在可接受范围内。
  • 妊娠期模拟暴露与非妊娠妇女相比无显著差异,提示无需剂量调整。
  • 该模型可用于评估妊娠期生理变化对药物PK的影响。

核心结论

  • PBPK模型预测妊娠期生理变化对齐拉西酮PK和暴露的影响,提示该特殊人群无需调整剂量。

研究设计与样本

  • 建立齐拉西酮全身PBPK模型,并在非妊娠人群(健康成人、儿童、老年人)中验证,再扩展至妊娠状态模拟。

主要发现

  • 健康成人中预测与观察的AUC、Cmax和tmax的倍数差异分别为0.94-1.09、0.89-1.40和0.80-1.08。
  • 儿童和老年人群中预测的AUC、Cmax和tmax均在观察值的两倍范围内。
  • 妊娠妇女模拟暴露与非妊娠妇女相比无显著差异。

临床怎么用

  • 临床可参考该模型结果,妊娠期使用齐拉西酮时无需常规调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Pregnancy is associated with physiological changes that alter the pharmacokinetics (PK) of drugs. The aim of this study was to predict the PK of ziprasidone in pregnant women. METHODS: A full physiologically-based pharmacokinetic (PBPK) model of ziprasidone was developed and validated for the non-pregnant population (healthy adults, paediatrics, geriatrics), and this was extended to the pregnant state to assess the change in PK profile of ziprasidone throughout pregnancy. RESULTS: The PBPK model successfully predicted the ziprasidone disposition in healthy adult volunteers, wherein the predicted and observed AUC, Cmax and tmax were within the fold-difference of 0.94-1.09, 0.89-1.40 and 0.80-1.08, respectively. The paediatric and geriatric population, also showed predicted AUC, Cmax and tmax within a two-fold range of the observed values. The simulated exposure in pregnant women using a p-PBPK model showed no significant difference when compared to non-pregnant women. CONCLUSIONS: The PBPK model predicted the impact of physiological changes during pregnancy on PK and exposure of ziprasidone, suggesting that dose adjustment is not necessary in this special population.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Biesdorf C, Martins FS, Sy SKB, et al. Physiologically-based pharmacokinetics of ziprasidone in pregnant women. Br J Clin Pharmacol. 2019. PMID: 30669177. doi:10.1111/bcp.13872

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。